PET imaging for CLDN18.2 in cancer patients
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study uses a special PET scan to look for a protein called CLDN18.2 on cancer cells. It may help doctors better understand certain cancers like stomach, pancreas, bile duct, or esophageal cancer and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have a known or suspected cancer (like stomach, pancreas, bile duct, or esophageal cancer)
- Be in generally good health
- Be able to lie still for a PET/MR or PET/CT scan
- Agree to use effective birth control if you are of childbearing age
- Be willing to follow the study procedures and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
This study tests a new type of PET scan (a special imaging test) that can detect a protein called claudin 18.2 in pancreatic cancer and stomach cancer. The scan may help doctors better understand your cancer and plan treatment.
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.